Mundipharma International Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mundipharma International Limited
Cidara partners its antiviral conjugate platform for seasonal and pandemic influenza with Janssen, which also gets option rights to an AVC candidate for respiratory syncytial virus.
Plus deals involving I-Mab/Complix, Lupin/Endoceutics, Genome & Co/Pfizer/Merck KGaA, Genome & Co/Debiopharm, Exelixis/WuXi, Intas/Foresee, Wugen/Alpha Biosciences
Public Company Edition: US initial public offerings are reawakening from a brief nap as Prometheus and Longboard prepare IPOs for launch. Also, Halozyme sells $700m worth of notes and Karuna’s $250m stock sale leads recent follow-on offerings.
A confluence of factors promoting the rapid adoption of health care AI is expected to make 2021 a pivotal year for the technology, as demonstrated by product launches at RSNA 2020.
- OTC, Consumer
- Controlled Release
- Other Names / Subsidiaries
- Cinfa Biotech GmbH
- Mundipharma Biologics S.L.
- Mundipharma EDO GmbH
- Napp Pharmaceuticals Ltd.
- Tolmar Australia Pty. Ltd.